| Maureen F Mckone, APRN | |
|
100 Kenyon Ave, Wakefield, RI 02879-4216 | |
| (401) 788-1277 | |
| (401) 788-1514 |
| Full Name | Maureen F Mckone |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 38 Years |
| Location | 100 Kenyon Ave, Wakefield, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336215664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0809X | Clinical Nurse Specialist - Psychiatric/mental Health, Adult | RN38065 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
News Archive
A single-use, self-administered microneedle technology developed by UConn faculty to provide immunization against infectious diseases has recently been validated by preclinical research trials.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
Taking the first deep dive into how the immune system is behaving in patients with multisystem inflammatory syndrome in children (MIS-C), researchers at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania have found that children with this condition have highly activated immune systems that, in many ways, are more similar to those of adults with severe COVID-19.
CAIRE Inc. formally announced the launch of the new SAROS™ 15 oxygen concentrator for combat casualty care today at its respiratory Center of Excellence in Ball Ground.
› Verified 9 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548506793 PECOS PAC ID: 2567455082 Enrollment ID: O20130528000089 |
News Archive
A single-use, self-administered microneedle technology developed by UConn faculty to provide immunization against infectious diseases has recently been validated by preclinical research trials.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
Taking the first deep dive into how the immune system is behaving in patients with multisystem inflammatory syndrome in children (MIS-C), researchers at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania have found that children with this condition have highly activated immune systems that, in many ways, are more similar to those of adults with severe COVID-19.
CAIRE Inc. formally announced the launch of the new SAROS™ 15 oxygen concentrator for combat casualty care today at its respiratory Center of Excellence in Ball Ground.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maureen F Mckone, APRN 1463 Frenchtown Rd, East Greenwich, RI 02818-1310 Ph: (401) 339-2920 | Maureen F Mckone, APRN 100 Kenyon Ave, Wakefield, RI 02879-4216 Ph: (401) 788-1277 |
News Archive
A single-use, self-administered microneedle technology developed by UConn faculty to provide immunization against infectious diseases has recently been validated by preclinical research trials.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
Taking the first deep dive into how the immune system is behaving in patients with multisystem inflammatory syndrome in children (MIS-C), researchers at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania have found that children with this condition have highly activated immune systems that, in many ways, are more similar to those of adults with severe COVID-19.
CAIRE Inc. formally announced the launch of the new SAROS™ 15 oxygen concentrator for combat casualty care today at its respiratory Center of Excellence in Ball Ground.
› Verified 9 days ago
Ms. Christine Boie, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 100 Kenyon Ave, Wakefield, RI 02879 Phone: 401-788-1277 | |
Maryann Abney, APRN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 24 Salt Pond Rd Ste H1, Wakefield, RI 02879 Phone: 401-789-3694 Fax: 401-789-3748 | |
Christine Stout, APRN Clinical Nurse Specialist Medicare: May Accept Medicare Assignments Practice Location: 100 Kenyon Ave, Wakefield, RI 02879 Phone: 401-788-1430 Fax: 401-783-2629 |